Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The appetite suppressant fenfluramine, a serotonin uptake inhibitor, has been implicated in the development of primary pulmonary hypertension (PPH). The effect of fenfluramine on the pressor response to endothelin-1 (ET-1) in the canine pulmonary circulation was determined using the isolated perfused dog lung. Pulmonary vascular resistance was measured using vascular occlusion techniques. Group 1 (n = 4) consisted of isolated lung lobes treated with 10-8 M ET-1 alone. For group 2 (n = 4) and group 3 (n = 4), dogs were given 15 mg fenfluramine daily for 14 days prior to sacrifice for isolated lung perfusion. In group 2, lobes were treated with 10-7 M fenfluramine after lung isolation. In group 3, the isolated lobes were treated with 10-8 M ET-1 similar to group 1. Acute treatment of the isolated lobes in group 2 with 10-7 M fenfluramine increased pulmonary arterial pressure. In group 3, administration of 10-8 M ET-1 potentiated the effect of ET-1 on post-capillary resistance relative to group 1, and elicited an increase in precapillary resistance, an effect not present in group 1. These results indicate that chronic fenfluramine exposure potentiates the pulmonary vasoconstrictor response to ET-1, and suggests that elevated levels of serotonin may 'prime' the pulmonary circulation to become hyperreactive to other vasoactive substances possibly leading to the development of disease states such as primary pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)183-187
Number of pages5
JournalPulmonary Pharmacology and Therapeutics
Volume11
Issue number2-3
DOIs
StatePublished - Jan 1 1998

Fingerprint

Fenfluramine
Endothelin-1
Canidae
Lung
Pulmonary Circulation
Capillary Resistance
Dogs
Appetite Depressants
Serotonin Uptake Inhibitors
Vasoconstrictor Agents
Vascular Resistance
Blood Vessels
Serotonin
Arterial Pressure
Perfusion

Keywords

  • Endothelin-1
  • Fenfluramine
  • Pulmonary vascular resistance
  • Pulmonary vasoconstriction
  • Serotonin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1. / Barman, Scott A; Isales, Carlos M.

In: Pulmonary Pharmacology and Therapeutics, Vol. 11, No. 2-3, 01.01.1998, p. 183-187.

Research output: Contribution to journalArticle

@article{8d053d2fdf7e4eaa8e025afb57d1cb33,
title = "Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1",
abstract = "The appetite suppressant fenfluramine, a serotonin uptake inhibitor, has been implicated in the development of primary pulmonary hypertension (PPH). The effect of fenfluramine on the pressor response to endothelin-1 (ET-1) in the canine pulmonary circulation was determined using the isolated perfused dog lung. Pulmonary vascular resistance was measured using vascular occlusion techniques. Group 1 (n = 4) consisted of isolated lung lobes treated with 10-8 M ET-1 alone. For group 2 (n = 4) and group 3 (n = 4), dogs were given 15 mg fenfluramine daily for 14 days prior to sacrifice for isolated lung perfusion. In group 2, lobes were treated with 10-7 M fenfluramine after lung isolation. In group 3, the isolated lobes were treated with 10-8 M ET-1 similar to group 1. Acute treatment of the isolated lobes in group 2 with 10-7 M fenfluramine increased pulmonary arterial pressure. In group 3, administration of 10-8 M ET-1 potentiated the effect of ET-1 on post-capillary resistance relative to group 1, and elicited an increase in precapillary resistance, an effect not present in group 1. These results indicate that chronic fenfluramine exposure potentiates the pulmonary vasoconstrictor response to ET-1, and suggests that elevated levels of serotonin may 'prime' the pulmonary circulation to become hyperreactive to other vasoactive substances possibly leading to the development of disease states such as primary pulmonary hypertension.",
keywords = "Endothelin-1, Fenfluramine, Pulmonary vascular resistance, Pulmonary vasoconstriction, Serotonin",
author = "Barman, {Scott A} and Isales, {Carlos M}",
year = "1998",
month = "1",
day = "1",
doi = "10.1006/pupt.1998.0135",
language = "English (US)",
volume = "11",
pages = "183--187",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "2-3",

}

TY - JOUR

T1 - Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1

AU - Barman, Scott A

AU - Isales, Carlos M

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The appetite suppressant fenfluramine, a serotonin uptake inhibitor, has been implicated in the development of primary pulmonary hypertension (PPH). The effect of fenfluramine on the pressor response to endothelin-1 (ET-1) in the canine pulmonary circulation was determined using the isolated perfused dog lung. Pulmonary vascular resistance was measured using vascular occlusion techniques. Group 1 (n = 4) consisted of isolated lung lobes treated with 10-8 M ET-1 alone. For group 2 (n = 4) and group 3 (n = 4), dogs were given 15 mg fenfluramine daily for 14 days prior to sacrifice for isolated lung perfusion. In group 2, lobes were treated with 10-7 M fenfluramine after lung isolation. In group 3, the isolated lobes were treated with 10-8 M ET-1 similar to group 1. Acute treatment of the isolated lobes in group 2 with 10-7 M fenfluramine increased pulmonary arterial pressure. In group 3, administration of 10-8 M ET-1 potentiated the effect of ET-1 on post-capillary resistance relative to group 1, and elicited an increase in precapillary resistance, an effect not present in group 1. These results indicate that chronic fenfluramine exposure potentiates the pulmonary vasoconstrictor response to ET-1, and suggests that elevated levels of serotonin may 'prime' the pulmonary circulation to become hyperreactive to other vasoactive substances possibly leading to the development of disease states such as primary pulmonary hypertension.

AB - The appetite suppressant fenfluramine, a serotonin uptake inhibitor, has been implicated in the development of primary pulmonary hypertension (PPH). The effect of fenfluramine on the pressor response to endothelin-1 (ET-1) in the canine pulmonary circulation was determined using the isolated perfused dog lung. Pulmonary vascular resistance was measured using vascular occlusion techniques. Group 1 (n = 4) consisted of isolated lung lobes treated with 10-8 M ET-1 alone. For group 2 (n = 4) and group 3 (n = 4), dogs were given 15 mg fenfluramine daily for 14 days prior to sacrifice for isolated lung perfusion. In group 2, lobes were treated with 10-7 M fenfluramine after lung isolation. In group 3, the isolated lobes were treated with 10-8 M ET-1 similar to group 1. Acute treatment of the isolated lobes in group 2 with 10-7 M fenfluramine increased pulmonary arterial pressure. In group 3, administration of 10-8 M ET-1 potentiated the effect of ET-1 on post-capillary resistance relative to group 1, and elicited an increase in precapillary resistance, an effect not present in group 1. These results indicate that chronic fenfluramine exposure potentiates the pulmonary vasoconstrictor response to ET-1, and suggests that elevated levels of serotonin may 'prime' the pulmonary circulation to become hyperreactive to other vasoactive substances possibly leading to the development of disease states such as primary pulmonary hypertension.

KW - Endothelin-1

KW - Fenfluramine

KW - Pulmonary vascular resistance

KW - Pulmonary vasoconstriction

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0032056050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032056050&partnerID=8YFLogxK

U2 - 10.1006/pupt.1998.0135

DO - 10.1006/pupt.1998.0135

M3 - Article

VL - 11

SP - 183

EP - 187

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 2-3

ER -